A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Small, Eric Jay
Lance, Raymond S.
Redfern, Charles H.
Millard, Frederick E.
Gardner, Thomas A.
Karsh, Lawrence Ivan
Dawson, Nancy Ann
McCoy, Candice
Stubbs, Andrew
DeVries, Todd
dela Rosa, Corazon P.
Sheikh, Nadeem A.
Shore, Neal D.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[3] Sharp Clin Oncol Res, San Diego, CA USA
[4] Moores UCSD Canc Ctr, San Diego, CA USA
[5] Urol Indiana Univ Hlth, Indianapolis, IN USA
[6] Urol Ctr Colorado, Denver, CO USA
[7] Georgetown Univ Med Ctr, Washington, DC USA
[8] Dendreon Corp, Seattle, WA USA
[9] Carolina Urol Res Ctr, Myrtle Beach, SC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5047
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [42] Phase I trial of docetaxel (D), prednisone, and pasireotide (P) (SOM230) in metastatic castrate-resistant prostate cancer (mCRPC).
    Vankayala, Hema M.
    Heilbrun, Lance K.
    Dobson, Kimberlee
    Stark, Karri
    Li, Jing
    Smith, Daryn W.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] SIPULEUCEL-T IN AFRICAN AMERICANS: A SUBGROUP ANALYSIS OF THREE PHASE 3 TRIALS OF SIPULEUCEL-T IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER
    McLeod, David G.
    Quinn, David I.
    Cullen, Jennifer
    Whitmore, James B.
    JOURNAL OF UROLOGY, 2012, 187 (04): : E388 - E388
  • [44] Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer
    Heath, Elisabeth I.
    Thakur, Archana
    Chen, Wei
    Hwang, Clara
    Paller, Channing J.
    Cackowski, Frank C.
    Boerner, Julie L.
    Heilbrun, Lance
    Smith, Melanie P.
    Schalk, Dana L.
    Schienschang, Amy
    Whitaker, Sarah A.
    Polend, Amanda
    Smith, Daryn
    Vaishampayan, Ulka N.
    Dickow, Brenda
    Lum, Lawrence G.
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (07): : 1715 - 1725
  • [45] Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T
    Dorff, Tanya
    Hirasawa, Yosuke
    Acoba, Jared
    Pagano, Ian
    Tamura, David
    Pal, Sumanta
    Zhang, Minlu
    Waitz, Rebecca
    Dhal, Abhilash
    Haynes, Winston
    Shon, John
    Scholz, Mark
    Furuya, Hideki
    Chan, Owen T. M.
    Huang, Jeffrey
    Rosser, Charles
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)
  • [46] Does Pretreatment with Abiraterone Acetate (AA) Or Enzlutamide (ENZA) Affect the Efficacy of Subsequent Cabazitaxel Chemotherapy in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)?
    Body, A.
    Pranavan, G.
    Malik, L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 56 - 56
  • [47] A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC)
    Karzai, Fatima H.
    Shah, Avani Atul
    Ojemuyiwa, Michelle A.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Dawson, Nancy Ann
    Arlen, Philip M.
    Theoret, Marc Robert
    Wright, John Joseph
    Chen, Clara
    Trepel, Jane B.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [48] Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials
    Small, E. J.
    Higano, C. S.
    Kantoff, P. W.
    Whitmore, J. B.
    Frohlich, M. W.
    Petrylak, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC).
    Mckay, Rana R.
    Werner, Lillian
    Jones, Alexandra
    Choudhury, Atish Dipankar
    Pomerantz, Mark
    Sweeney, Christopher
    Bubley, Glenn J.
    Slovin, Susan F.
    Morris, Michael J.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Real-world outcome with abiraterone acetate plus prednisone in Asian men with metastatic castrate-resistant prostate cancer: The Singapore experience
    Chan, Johan
    Yap, Shi Yin
    Fong, Yian Ching
    Lim, Heng Chi
    Toh, Chee Keong
    Ng, Quan Sing
    Rajasekaran, Tanujaa
    Chua, Melvin
    Lee, Lui Shiong
    Wong, Alvin
    Loh, Ker Yun
    Chow, Marcus
    Wong, Siew Wei
    Kanesvaran, Ravindran
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (01) : 75 - 79
12345